About this document

56649539D Article 001 by sravan.6595 is a document available to read on EtoBox.

This article discusses the design of novel BCR-ABL inhibitors aimed at treating chronic myeloid leukemia (CML) with improved cardiac safety. The study highlights the limitations of existing tyrosine kinase inhibitors (TKIs), particularly ponatinib, which is effective against the T315I mutation but has significant cardiotoxicity. The authors report the identification of two new compounds, 33a and 36a, that effectively inhibit both native and mutant BCR-ABL kinases while demonstrating enhanced cardiac safety.

Author

sravan.6595

Language

EN